Subsequent radioreceptor binding analysis indicated that the drug-induced changes in oligomer formation were not readily explained by alterations in receptor density. These observations support the hypothesis that long-term drug exposure differentially alters A 2A /D 2 receptor oligomerization and provide the first demonstration for the use of BiFC to monitor drugmodulated GPCR oligomerization.
Subsequent radioreceptor binding analysis indicated that the drug-induced changes in oligomer formation were not readily explained by alterations in receptor density. These observations support the hypothesis that long-term drug exposure differentially alters A 2A /D 2 receptor oligomerization and provide the first demonstration for the use of BiFC to monitor drugmodulated GPCR oligomerization.
A growing number of G protein-coupled receptors (GPCRs) have been shown to exist as oligomers with unique functional properties and physiological relevance (Pin et al., 2007) . Evidence suggests that A 2A and D 2 form receptor heteromers. Both receptors are highly expressed in the striatum, where they colocalize on spiny neurons (Fink et al., 1992) . The receptors have opposing actions on adenylyl cyclase activity, through coupling to G␣ s (A 2A ) or G␣ i/o (D 2 ) proteins. Biochemical and behavioral evidence also indicates antagonistic A 2A /D 2 interactions (Ferre et al., 1991; Agnati et al., 2003; Fuxe et al., 2007) . Moreover, persistent D 2 activation sensitizes A 2A receptor-stimulated cAMP accumulation (Vortherms and Watts, 2004) . A 2A and D 2 have been shown to oligomerize in resonance energy transfer as well as coimmunoprecipitation experiments (Hillion et al., 2002; Canals et al., 2003; Kamiya et al., 2003) . Therefore, a direct A 2A /D 2 interaction may account for the antagonism between the two receptors. In addition to forming heteromers, A 2A and D 2 also exist as homomers (Lee et al., 2000; Armstrong and Strange, 2001; Gazi et al., 2003; Canals et al., 2004; Guo et al., 2005) . The stoichiometry of A 2A and D 2 in A 2A /D 2 heteromers is unknown, as is the relative proportion of A 2A and D 2 recep-tors engaging in hetero-or in homomers (or existing as monomeric receptors). Although A 2A and D 2 homo-and heteromerization was shown to be constitutive and was not affected by acute receptor activation (Canals et al., 2003; Gazi et al., 2003; Canals et al., 2004) , the effect of persistent receptor activation or antagonism on the relative homo-/heteromer population has not been investigated.
Bimolecular fluorescence complementation (BiFC) is an emerging technique to monitor protein-protein interactions (Hu et al., 2002; Shyu et al., 2006) . Whereas most currently available techniques are restricted to the detection of two interacting proteins, multicolor BiFC (i.e., the reconstitution of distinct spectral GFP variants) allows the simultaneous detection of two distinct protein-protein interactions in living cells (Hu and Kerppola, 2003) . We have applied multicolor BiFC to simultaneously visualize A 2A /D 2 heteromers and A 2A homomers in the Cath.a differentiated (CAD) neuronal cell model (Qi et al., 1997 Cell Culture. CAD cells were maintained as described previously (Vortherms and Watts, 2004) .
Expression Vectors. Full-length human D 2L , A 2A , or D 1 cDNAs were amplified by polymerase chain reaction using oligonucleotides incorporating EcoRI and XbaI or XhoI restriction sites and omitting stop codons. Polymerase chain reaction fragments digested with EcoRI/XbaI or EcoRI/XhoI were ligated into the corresponding sites from pBiFC vectors (Shyu et al., 2006) . These vectors contain fragments from the yellow Venus [V (Nagai et al., 2002) ] or the cyan Cerulean [C (Rizzo et al., 2004) ] enhanced fluorescent proteins. NTerminal fragments (VN or CN) include residues 1 to 172, whereas C-terminal fragments (VC or CC) include residues 155 to 238. Cloning into pBiFC vectors incorporates MYC (pBiFC-VN), HA (pBiFC-VC and pBiFC-CC), or FLAG (pBiFC-CN) N-terminal epitope tags to the fusion proteins to ease their detection. Receptor fusions to Venus or Cerulean were obtained by swapping BiFC fragments with Venus or Cerulean coding sequences. Constructs were verified by DNA sequencing.
Imaging and Image Analysis. CAD cells were grown to 70% confluence in four-well Lab-Tek coverslips (Nalge Nunc International, Rochester, NY) and transfected using 1 l/well Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to the manufacturer's recommendations. DNA amounts per well were 500 ng (D 2L and D 1 constructs), 200 ng (A 2A -VN), 100 ng (A 2A -CC, A 2A -CN), or 20 ng (mCherry-Mem, YFP-Endo, YFP-Golgi, and YFP-ER). Twenty-four hours after transfection, the growth media was replaced with phosphate-buffered saline, and images were captured using a chargecoupled device camera mounted on a TE2000-U inverted fluorescence microscope (Nikon Instruments Inc., Melville, NY) equipped with a 100-W mercury lamp and band-pass filters (Chroma, Rockingham, VT) for Venus (excitation at 500/20 nm; emission at 535/30 nm), Cerulean (excitation at 430/25 nm; emission at 470/30 nm), or mCherry (excitation at 572 nm/23 nm). Fluorescent images were acquired using the MetaMorph software (Molecular Devices, Sunnyvale, CA) and AutoDeblur (MediaCybernetics, Bethesda, MD) was used for three-dimensional deconvolution. Blind selection and analysis of the cells avoided experimental bias. Quantification of BiFC signals was performed as described previously (Hu et al., 2002) , using the ImageJ software (http://rsb.info.nih.gov/ij/). Stacks of fluorescent images were analyzed as follows. Background fluorescence intensities were determined by measuring areas devoid of cells and were subtracted from each pixel intensity measurement. After background removal, pixel intensities were scaled by a factor equal to the inverse of the exposure time. Images from the mCherry-Mem membrane marker were used to select cells for analysis and to normalize BiFC signals. Bleed-through and cross-talk coefficients for Cerulean and Venus channels were calculated with cells expressing either V or C (or corresponding BiFC pairs). The C/V fluorescence ratio (noted x coefficient) in cells expressing only Venus was 0.00005 Ϯ 0.00002 (n ϭ 7), x in cells expressing VN/CC BiFC fragments was 0.00276 Ϯ 0.00065 (n ϭ 5), and the V/C fluorescence ratio (y coefficient) in cells expressing Cerulean was 0.00256 Ϯ 0.00018 (n ϭ 7). Corrected Venus (V cor ) and Cerulean (C cor ) signals were calculated using the equations V cor ϭ (V Ϫ yC)/1 Ϫ xy and C cor ϭ (C Ϫ xV)/1 Ϫ xy, with V and C indicating the measured Venus and Cerulean fluorescence intensities.
Protein Analysis. Protein concentration was determined using the BCA method (Pierce, Rockford, IL). BiFC-tagged GPCR expression was quantified by dot-blot (Zeder-Lutz et al., 2006) . Cell suspensions were lysed with SDS [2% (w/v)], and proteins (5 g) were spotted onto nitrocellulose membranes using a bio-dot apparatus (Bio-Rad Laboratories, Hercules, CA). Anti-HA (Sigma) or anti-c-MYC (Clontech, Mountain View, CA) mouse antibodies as well as anti-mouse-HRP conjugated antibodies (Bio-Rad Laboratories) were used for immunodetection. Enhanced chemiluminescence signals (ECLϩ, GE healthcare) were detected and quantified using a Typhoon scanner and the ImageQuant software (Amersham, Chalfont St. Giles, Buckinghamshire, UK). antagonist, respectively. 5Ј-N-Methylcarboxamidoadenosine (MECA; 1 M) and CGS15943 (1 M) were used as A 2A agonist and antagonist, respectively. Dopamine (10 M) and butaclamol (10 M) were used as D 1 -like agonist and antagonist, respectively. Stimulations were performed in the presence of the phosphodiesterase inhibitors 3-isobutyl-1-methylxanthine (500 M) or Ro 20-1724 (100 M for MECA stimulations) and terminated by the addition of 3% trichloroacetic acid. A competitive binding assay was used for cAMP quantification (Vortherms and Watts, 2004) .
Radioligand Binding Experiments. Radioreceptor binding experiments were performed as described previously (Watts and Neve, 1996) , with minor modifications. A point binding technique was employed to estimate A 2A and D 2 receptor densities, using saturating concentrations of radioligand. These concentrations were based on full receptor isotherms, which revealed similar binding properties between the fusion proteins and wild-type receptors (data not shown). Twenty-four hours after transfection and 18 h after drug treatment, cells in 12-well plates were washed and lysed in 1 ml of ice-cold lysis buffer (1 mM HEPES and 2 mM EDTA, pH 7.4) and membranes were collected by centrifugation (10 min at 13,000g). Membrane pellets were resuspended by mechanical homogenation in 500 l of receptor binding buffer (50 mM Tris and 4 mM MgCl 2 , pH 7.4). Membranes for A 2A receptor experiments were treated with 2 U/ml adenosine deaminase (Roche Applied Science, Indianapolis, IN) at 37°C for 30 min to remove endogenous adenosine. Treated membranes (10-20 g of protein in 100 l) were added in duplicate to assay tubes to determine total and nonspecific binding (defined by 50 M adenosine-5ЈN-ethylcarboxamide). All tubes contained binding assays were terminated by filtration onto FB glass fiber plates with ice-cold wash buffer (10 mM Tris and 0.9% NaCl) using a cell harvester (FilterMate; Packard). Radioactivity was determined using a Packard TopCount scintillation counter. Specific binding for each sample was determined as the difference between the average counts for total versus nonspecific binding. The specific binding values were normalized to the amount of protein added per well, as determined by the Pierce BCA Protein Assay. Within an experiment, drug treatments were performed in triplicate, and for each of these, total and nonspecific binding conditions were performed in duplicate.
Statistical Analysis. Statistical analysis was performed using Prism (GraphPad Software Inc., San Diego, CA). Student's t test or one-way ANOVA followed by post hoc tests are indicated with the corresponding p values in the figure legends. A p value Ͻ 0.05 was considered significant. blocked by the addition of the D 2 antagonist spiperone (Fig.  1A) . Because CAD cells endogenously express A 2A (Vortherms and Watts, 2004) (Fig. 1B) (Fig. 1C) . The results of these experiments demonstrated that fluorescence complementation did not disrupt quinpirole-or MECA-stimulated receptor function. Function of the dopamine D 1 receptor (D 1 ) fusion to VC was also addressed in CAD cells expressing D 1 or D 1 -VC. D 1 -mediated dopamine stimulation of cAMP accumulation was similar in both transfections and was blocked by the dopamine receptor antagonist butaclamol (Fig. 1D) . Together, these results revealed that -VN and -VC fusion receptors retained ligand-dependent function in the conditions tested. Because Cerulean and Venus have virtually identical structures, we assume that the functional data described above are relevant for receptor fusions to both Venus and Cerulean fragments.
Results and Discussion
Subsequent experiments used the novel BiFC fusion receptors to explore the localization and specificity of fluorescence complementation in CAD cells. Cells coexpressing A 2A -VN and D 2L -VC exhibited robust Venus fluorescence detected in whole-cell fluorescence measurements ( Fig. 2A) or using microscopy (Fig. 2B) . Because biochemical evidence suggests a weak A 2A /D 1 interaction (Hillion et al., 2002) , control experiments in which D 1 -VC replaced D 2L -VC were used to address the specificity of the fluorescent complementation. Fluorescent signals from cells expressing A 2A -VN and D 2L -VC were significantly higher than signals in A 2A -VN and D 1 -VC transfections (Fig. 2, A and B) . Analysis of receptor expression levels in dot-blot experiments suggested that this difference was not a result of reduced D 1 -VC protein expression levels compared with D 2L -VC (Fig. 2C) (Fig. 2, B and D) . Signals were also detected in intracellular compartments, presumably reflecting receptor internalization or localization at the endoplasmic reticulum (ER). In experiments using A 2A -VN and D 1 -VC pairs, BiFC signal intensity at the plasma membrane was reduced by more than 60% compared with A 2A /D 2L signals (Fig. 2, B and  D) . Cells expressing A 2A -VN and D 1 -VC seemed to display an increased proportion of intracellular fluorescence (Fig. 2E) , suggesting more extensive internalization or less efficient export to the plasma membrane of A 2A /D 1 , possibly as a consequence of quality-control mechanisms at the endoplasmic reticulum (Bulenger et al., 2005) . (Fig. 3, D and E) . The inclusion of sulpiride prevented this change and reversed the fluorescence ratio. Intracellular fluorescence was similarly influenced by the drug treatments, indicating that changes of fluorescence intensity at the plasma membrane did not solely result from altered receptor trafficking. To validate the microscopic analysis, nonbiased whole-cell fluorescence measurements were taken (Fig. 3F) . These studies also revealed a decrease in Venus ( The differential effect of ligands on BiFC fluorescence may reflect ligand-dependent alterations of receptor density. Thus, we measured D 2 and A 2A receptor levels in cells transfected with D 2L -VN, A 2A -CN, and A 2A -CC using single-point radioreceptor binding assays. Both quinpirole and sulpiride treatments lead to increased D 2 receptor density, whereas MECA and CGS15943 had no effect on D 2 expression (Table  1 ). An up-regulation of D 2L -VN protein levels after quinpirole, sulpiride, or spiperone treatments was also revealed in dot-blot experiments (data not shown). These results are consistent with previous reports (Filtz et al., 1994; Zhang et al., 1994; Starr et al., 1995) and likely reflect a pharmacological chaperone effect (Bernier et al., 2004; Conn et al., 2007) (Fig. 3) .
We used a novel approach to study GPCR interactions and observed ligand-mediated effects on oligomer formation (Pfleger and Eidne, 2005) . GPCR oligomerization has been proposed to be altered in pathogenic situations or by longterm drug administration such as in Parkinson's disease therapies (Javitch, 2004; Fuxe et al., 2007) . Therapies for Parkinson's disease largely rely on long-term dopamine receptor stimulation with L-DOPA to compensate for the loss of striatal dopaminergic neurons and are often accompanied with dyskinesias. A 2A antagonists have recently been applied with reduced L-DOPA doses in clinical studies and were shown to prevent and alleviate L-DOPA-induced dyskinesias (Schwarzschild et al., 2006; Morelli et al., 2007) . Although a precise understanding of the molecular mechanisms underlying this adjunctive therapy are lacking, it has been proposed that long-term L-DOPA treatment may alter A 2A and D 2 homo-and heteromerization on striatal neurons (Antonelli et al., 2006 (Vortherms and Watts, 2004) . Moreover, a D 2 agonist-induced enhancement of A 2A signaling also provides a molecular explanation for the beneficial effects of A 2A antagonists in L-DOPA-induced dyskinesias (Morelli et al., 2007) . These observations and the results in the present study highlight the applicability of multicolor BiFC as a novel approach to examine physiologically relevant GPCR interactions. Moreover, it may offer a novel technique for screening drugs that target GPCR oligomers.
